Xenoport -
Looks like he should have stayed at Xenoport, their stock has gone from $10 to $50 over the last couple years. Maybe Tran didn't like the prospects for the "restless legs syndrome" program. Restless leg syndrome, now that sounds like a serious life threatening condition, lol -
>>> Xenoport, Inc. operates as a biopharmaceutical company in the United States. It focuses on developing a portfolio of internally discovered product candidates that utilize the body's natural nutrient transporter mechanisms. The company's products include XP13512, a transported prodrug of gabapentin, which is in Phase 3 clinical trials for the treatment of restless legs syndrome; XP13512 for neuropathic pain, including post-herpetic neuralgia, which is in Phase 2a clinical trial; and XP19986, a transported prodrug of R-baclofen for the treatment of gastroesophageal reflux disease and spasticity, which is in a Phase 2a clinical trial. It also develops XP21279, a transported prodrug of levodopa or L-Dopa that is in preclinical development for the treatment of Parkinson's disease; and XP20925, a transported prodrug of propofol, which is in preclinical development for the treatment of migraine and chemotherapy-induced nausea and vomiting. Xenoport has strategic alliances with Astellas Pharma, Inc. to develop and commercialize XP13512 in Japan, Korea, the Philippines, Indonesia, Thailand, and Taiwan; and Glaxo Group Limited to develop and commercialize XP13512 worldwide. The company was founded in 1999 and is based in Santa Clara, California. <<<
AI
Market Data 
Markets 
